Turning Point Therapeutics Inc

Turning Point Therapeutics — Investor Presentation (October 2020)

30 slides from Turning Point Therapeutics's investor presentation, Oct 26, 2020

  1. Slide 1: Next-Generation Precision Oncology Medicines Company Overview

    October 2020 Next-Generation Precision Oncology Medicines Company Overview Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and projected timelines, bus

  3. Slide 3: Significant Pipeline Progress in 2020

    Significant Pipeline Progress in 2020 Repotrectinib Third FDA Fast Track Designation Granted Reported Early, Interim Data from TRIDENT-1 Phase 2 Registrational Study Continued Site Activation, Now >80 Sites in 14 Countries in TRIDENT-1 Study Received FDA Feedback to Potentially Accelerate Developmen

  4. Slide 4: Our Vision Drives Our Strategy

    Our Vision Drives Our Strategy Pipeline Expansion Clinical Excellence Leadership in Precision Oncology Potential for Best-in-Class Products Addressing Patients with High Unmet Need in TKI-Naïve and Resistance Settings Deep Oncology Development Expertise Rapid Clinical Proof-of-Concept Data Therapeut

  5. Slide 5: Pipeline: Four Ongoing Clinical Studies Against Validated Oncogenic Targets

    Discovery Preclinical Early Stage Clinical Development Late Stage Clinical Development Regulatory Submission Repotrectinib (ROS1/TRK)¹ TRIDENT-1: Advanced NSCLC (ROS1) and solid tumors (NTRK) Pediatric advanced solid tumors TRIDENT-2: KRAS-targeting combination TPX-0022 (MET)² SHIELD-1: Advanced sol

  6. Slide 6: Patient Population and Biomarker Frequency

    Patient Population and Biomarker Frequency Repotrectinib TPX-0022 TPX-0046 TPX-0131 Advanced NSCLC2 Advanced Solid Tumors Advanced NSCLC2 EGFR Mutant TKI-Resistant Advanced NSCLC2,7 Advanced Gastric Cancer Advanced NSCLC2 Advanced Medullary Thyroid Cancer Advanced Papillary Thyroid Cancer Advanced N

  7. Slide 7: Repotrectinib: A Highly Selective ROS1/TRK Inhibitor

    Repotrectinib: A Highly Selective ROS1/TRK Inhibitor

  8. Slide 8: Repotrectinib: Potential Best-in-Class ROS1 and NTRK Targeted Therapy

    Highly potent, structurally differentiated: small (low molecular weight), compact, with a rigid 3D macrocycle Designed to bind completely inside the ATP pocket even in the presence of solvent front or gatekeeper mutations Potential to address resistance from prior lines of TKI therapy May also preve

  9. Slide 9: Repotrectinib Selectivity Profile Potentially Expands Opportunity

    Inhibits JAK2, SRC and FAK Leads to suppression of STAT3 and AKT signaling, major mechanisms of resistance Demonstrated synergy with AMG510, inhibiting KRASG12C tumor cell proliferation, suppressing receptor tyrosine kinase upregulation, reducing KRASG12C tumor cell cytokine release Demonstrated syn

  10. Slide 10: Repotrectinib Enhances Survival with AMG510 in KRASG12C Xenograft Model

    Repotrectinib combination shows a significant survival benefit in NSCLC KRASG12C xenograft model Builds on prior preclinical studies showing synergy with AMG510, inhibiting KRASG12C tumor cell proliferation, suppressing receptor tyrosine kinase upregulation, reducing KRASG12C tumor cell cytokine rel

  11. Slide 11: TRIDENT-1: Ongoing Phase 1/2 Study of Repotrectinib

    TRIDENT-1: An Ongoing Phase 1/2 Study of Repotrectinib in Patients with Advanced Solid Tumors Harboring ROS1, NTRK1-3 Rearrangements Phase 2 Early Interim Update Based on Data Cut-off of July 10, 2020

  12. Slide 12: TRIDENT-1 Efficacy Overview

    TRIDENT-1 Efficacy Overview – Early Phase 2 Data Compared to Phase 1 ¹ Represents the first 39 patients treated. In EXP-3 (Two prior TKIs with prior chemotherapy; N=10): No objective responses observed. EXP-3 to be modified to exclude patients treated with prior chemotherapy ² The seventh patient ac

  13. Slide 13: ROS1+ TKI Naïve Advanced NSCLC Patients

    ROS1+ TKI Naïve Advanced NSCLC Patients EXP-1 + Phase 1 ^Patient achieved an unconfirmed partial response after the data cutoff date and remained on treatment awaiting a confirmatory scan as of the early interim update on Aug. 19, 2020. uPR is not counted in cORR calculation. Phase 2 Data cutoff of

  14. Slide 14: ROS1+ TKI-Pretreated Advanced NSCLC Patients

    Phase 2 Phase 1+2 EXP-2: 1 Prior TKI with prior platinum chemotherapy Confirmed ORR (95% CI) 40% (5 – 85) n=5 50% (21 – 79) n=12 Duration of Response 4.5 – 5.6+ months (range) n=2 2.7+ – 11.1 months (range) n=6 EXP-4: 1 Prior TKI without prior platinum chemotherapy Confirmed ORR (95% CI) 67% (22 – 9

  15. Slide 15: NTRK+ TKI-Pretreated Advanced Solid Tumor Patients

    NTRK+ TKI-Pretreated Advanced Solid Tumor Patients in TRIDENT-1 EXP-6 + Phase 1 Confirmed ORR (95% CI) Duration of Response Phase 2 Data cutoff of 10 July 2020, responses confirmed by Physician Assessment per RECIST Phase 1 Data cutoff of 22 July 2019, responses confirmed by Blinded Independent Cent

  16. Slide 16: Phase 2 Safety Summary

    Generally well-tolerated Most treatment emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) were Grade 1 or 2 No Grade 4 or Grade 5 TRAEs The most commonly reported TEAE was low grade dizziness 83% (20/24) were Grade 1 No cases of dizziness have led to treatment discontinuat

  17. Slide 17: TRIDENT-1 Study Design

    Phase 2 TRIDENT-1 Study Design ROS1+ Advanced NSCLC NTRK+ Advanced Solid Tumors EXP-1 ROS1 TKI-Naïve (n=55) EXP-2 1 Prior ROS1 TKI AND 1 Platinum-Based Chemotherapy (n=60) EXP-3* 2 Prior ROS1 TKIs AND No Prior Chemotherapy (n=40) EXP-4 1 Prior ROS1 TKI AND No Prior Chemotherapy (n=60) EXP-5 TRK TKI-

  18. Slide 18: Advancing Three Additional Next-Generation Kinase Inhibitors

    Advancing Three Additional Next-Generation Kinase Inhibitors

  19. Slide 19: TPX-0022 is a Potent Inhibitor of MET, SRC, and CSF1R

    TPX-0022 is a Potent Inhibitor of MET, SRC, and CSF1R Tyrosine Kinases TPX-0022 is a compact 3-D macrocycle that was designed based on the MET crystal structure to efficiently bind the autoinhibitory conformation TPX-0022 is a potent MET inhibitor with activity against SRC and CSF1R SRC is a downstr

  20. Slide 20: SHIELD-1 Phase 1 Study of TPX-0022

    SHIELD-1 Phase 1 Study of TPX-0022 in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET Population Adults with advanced solid tumors MET genetic alterations assessed by local testing (exon 14 deletion, amplification, fusion, or oncogenic kinase domain mutation) Asymptomatic CN

  21. Slide 21: TPX-0022: Subject Disposition from SHIELD-1

    TPX-0022: Subject Disposition from SHIELD-1 Phase 1 Early, Interim Data Note: Data presented at 2020 EORTC-NCI-AACR Symposium. Data cutoff of 15-Oct-2020. a Patients with baseline measurable disease and at least one post-baseline scan b Patients on treatment but with no post-baseline scan as of data

  22. Slide 22: TPX-0022 Preliminary Safety Summary

    TPX-0022 has been generally well tolerated Most AEs were Grade 1 or 2 Most common TEAE was dizziness, likely due to off target TRK inhibition Infrequent dose modifications due to TEAE 5 (23%) patients with TEAEs that led to dose reduction 2 (9%) patients with TEAEs that led to drug discontinuation M

  23. Slide 23: TPX-0022: Preliminary Efficacy by Investigator Assessment

    Of 10 MET TKI-Naïve patients, 5 have achieved PRs 3 gastric/GE junction, 1 CRC, and 1 NSCLC 3 cPRs are ongoing with DOR range 1.0+ to 3.9+ months 2 uPR on treatment pending confirmation Of the 5 MET TKI-Pretreated NSCLC patients, 3 had stable disease All 5 patients were treated at 20 or 40 mg QD dos

  24. Slide 24: TPX-0022 Duration of Treatment

    TPX-0022 Duration of Treatment Note: Data presented at 2020 EORTC-NCI-AACR Symposium. Data cutoff of 15-Oct-2020. Duration of Treatment NSCLC (N=8): 3.4 to 34+ weeks CRC (N=4): 5.1 to 17 weeks GC/GEJ (N=3): 9.4+ to 23.6+ weeks

  25. Slide 25: TPX-0022 SHIELD-1 Early, Interim Data Key Takeaways

    TPX-0022 SHIELD-1 Phase 1 Early, Interim Data Key Takeaways Encouraging Early Initial Data in Ongoing Phase 1 SHIELD-1 Study TPX-0022 was generally well tolerated among 22 treated patients with 1 DLT at 120 mg QD^ Preliminary Phase 1 data suggest pan-tumor potential Responses observed in MET exon 14

  26. Slide 26: TPX-0046: Highly Potent, Selective RET Inhibitor

    TPX-0046: Highly Potent, Selective RET Inhibitor Note: Data presented at 2020 ASCO Conference. NR = Not reported. ¹ All of the compounds were tested on the same plates in multiple experiments and the data represents an average of the results. ² Data based on evaluation of corresponding proxy chemica

  27. Slide 27: TPX-0046 Phase 1/2 Study Ongoing

    TPX-0046 Phase 1/2 Study Ongoing Phase 1 Dose Escalation (n=~40)¹ Phase 2 (n= ~300) RP2D Multiple RET+ patients with solvent-front mutations previously treated with other RET inhibitors dosed with TPX-0046 in ongoing Phase 1/2 study RET Fusion+ NSCLC RET TKI-Naïve Adult advanced solid tumor patients

  28. Slide 28: TPX-0131: Highly Potent, Selective ALK Inhibitor

    TPX-0131: Highly Potent, Selective ALK Inhibitor Note: Data presented at 2020 AACR Conference. ¹ Shaw A et al., J Clin Oncol 37:1370-1379. TPX-0131 Differentiation Potently inhibit WT ALK and solvent front / compound mutations Solvent front mutation G1202R reported in ~42% of patient biopsies with a

  29. Slide 29: Anticipated Milestones

    Anticipated Milestones Repotrectinib World Conference on Lung Cancer TRIDENT-1 Data Presentation¹ Jan. 2021 Goal to achieve full TRIDENT-1 global site activation²; Provide update on overall study timeline Early 2021 Initiate TRIDENT-2 Phase 2 Combination Study in KRAS Mutant Non-Small Cell Lung Canc

  30. Slide 30: Next-Generation Precision Oncology Medicines Company Overview

    October 2020 Next-Generation Precision Oncology Medicines Company Overview

Turning Point Therapeutics — Investor Presentation (October 2020) on 6ix